AVITA Medical, Inc. (RCEL) Cash & Equivalents (2018 - 2026)

AVITA Medical (RCEL) has reported Cash & Equivalents for 9 consecutive years, with $9.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 25.19% year-over-year to $9.1 million; the trailing twelve-month figure through Jun 2026 stood at $9.1 million (down 25.19% YoY), and the FY2025 full-year result was $10.2 million, down 27.1% from the prior year.
• Cash & Equivalents eased to $9.1 million in Q2 2026 per RCEL's latest filing, from $10.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $50.9 million in Q3 2023 and bottomed at $9.1 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $21.7 million across 5 years, with a median of $18.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 79.37% in 2022, then surged 113.54% in 2023.
• Over 5 years, Cash & Equivalents stood at $18.2 million in 2022, then gained by 21.77% to $22.1 million in 2023, then plunged by 36.48% to $14.0 million in 2024, then dropped by 27.1% to $10.2 million in 2025, then decreased by 10.78% to $9.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $9.1 million, $10.2 million, and $15.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.